SCHEMBL298287

SCHEMBL298287

Cn1cc(Cc2cc(C3=CN(CC(=O)c4cccs4)C=CC3)[nH]n2)c2ccccc21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARG Q86W56 1/20 0.34
MAPT P10636 4/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
CMA1 P23946 3/20 0.34
ALDH1A1 P00352 5/20 0.34
KDM4E B2RXH2 3/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
GPR84 Q9NQS5 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
NPSR1 Q6W5P4 3/20 0.33
HSD17B10 Q99714 1/20 0.33
GAA P10253 1/20 0.32
PRKCA P17252 1/20 0.32
GSK3B P49841 1/20 0.32
LMNA P02545 2/20 0.32
HTT P42858 2/20 0.32
MAPK1 P28482 1/20 0.32
AHR P35869 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL661697 0.85 DAO (0.35) MAPTALDH1A1KDM4EGAALMNA
SCHEMBL27871690 0.84 CMA1 (0.33) MAPTCMA1ALDH1A1KDM4EGPR84
SCHEMBL297066 0.83 SMN1; SMN2 (0.37) MAPTSMN1; SMN2ALDH1A1KDM4EMEN1
SCHEMBL298661 0.78 KMT2A (0.37) MAPTSMN1; SMN2ALDH1A1KDM4EMEN1
SCHEMBL297726 0.76 MAPT (0.38) MAPTSMN1; SMN2ALDH1A1KDM4EMEN1
SCHEMBL299464 0.75 KMT2A (0.35) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL660685 0.66 ALDH1A1 (0.40) MAPTSMN1; SMN2ALDH1A1KDM4EMEN1
SCHEMBL27871675 0.66 KMT2A (0.33) MEN1KMT2A
SCHEMBL7808911 0.66 ALDH1A1 (0.48) MAPTSMN1; SMN2ALDH1A1KDM4EMEN1
SCHEMBL660175 0.65 HRH2 (0.34) MAPTSMN1; SMN2MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427432-A2 NOVEL HETEROCYCLIC COMPOUNDS Torrent Pharmaceuticals Limited (IN) 2012-03-14 EP claimed
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS DUTT CHAITANYA (IN) 2012-02-23 US claimed
WO-2010128528-A2 NOVEL HETEROCYCLIC COMPOUNDS TORRENT PHARMACEUTICALS LIMITED (IN) 2010-11-11 WO claimed
EP-2427432-A2 NOVEL HETEROCYCLIC COMPOUNDS Torrent Pharmaceuticals Limited (IN) 2012-03-14 EP disclosed
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS DUTT CHAITANYA (IN) 2012-02-23 US disclosed
WO-2010128528-A2 NOVEL HETEROCYCLIC COMPOUNDS TORRENT PHARMACEUTICALS LIMITED (IN) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS AGER, REN, AGT PARG 2297/4885MAPT 61/4885SMN1; SMN2 640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.